What Is Ozempic?

Ozempic (semaglutide) is a once-weekly injectable GLP-1 receptor agonist manufactured by Novo Nordisk, FDA-approved in December 2017 for adults with type 2 diabetes to improve blood sugar control and reduce major adverse cardiovascular events in those with established cardiovascular disease.

Formulation: Weekly subcutaneous injection (0.5 mL pen)

Mechanism: GLP-1 receptor agonist

Manufacturer: Novo Nordisk official patient site ↗

FDA Approved: 2017 — Key Trial: SUSTAIN-6 ↗ (ClinicalTrials.gov)

Who Is Ozempic For?

FDA-Approved Indication: Type 2 diabetes management (also used off-label for weight management)

Adults with type 2 diabetes mellitus (T2D) not adequately controlled with diet and exercise alone. Also indicated for cardiovascular risk reduction in T2D patients with established cardiovascular disease. Often prescribed off-label for weight management when Wegovy is unavailable.

Eligibility criteria: BMI criterion not required for T2D indication; used primarily in patients with established T2D

Dosing & Titration Schedule

The standard titration protocol for Ozempic (Semaglutide) allows your body to adjust gradually to the medication, minimizing GI side effects. Each dose is typically maintained for 4 weeks before escalation, though your prescriber may modify this based on tolerability.

Dose	Approx. Weeks	Frequency	Phase
0.25 mg	Wk 1–4	Weekly	▶ Starting dose
0.5 mg	Wk 5–8	Weekly	→ Escalation
1.0 mg	Wk 9–12	Weekly	→ Escalation
1.7 mg	Wk 13–16	Weekly	→ Escalation
2.4 mg	Wk 17–20	Weekly	★ Maintenance

Data source: FDA Prescribing Information for Ozempic. Individual titration may vary based on tolerability and clinical response.

Weight Loss & Glycemic Outcomes

Clinical trial evidence (SUSTAIN-6): ~5–10% (diabetes label); up to 14.9% in STEP-1 at 2.4 mg (Wegovy indication)

Cardiovascular benefit: Ozempic has demonstrated cardiovascular outcome benefits in clinical trials. Discuss cardiovascular risk reduction with your prescriber.

These figures are based on clinical trial populations meeting specific inclusion criteria. Real-world results may differ due to adherence, diet, activity level, and individual biology. Calculate your projected weight loss →

Side Effect Profile

The most commonly reported side effects of Ozempic are GI-related, typically most pronounced during dose escalation. They generally improve within 2–4 weeks at a stable dose.

•Nausea
•Vomiting
•Diarrhea
•Constipation
•Fatigue
•Injection Site Reaction
•Headache

For detailed guidance on managing specific side effects, see the Semaglutide side effects hub →

Cost Overview

Scenario	Estimated Monthly Cost
Cash pay (no insurance)	$900–$1,000/month
Commercial insurance	$25–$75/month with commercial insurance and Novo Nordisk savings card
Manufacturer savings program	Novo Nordisk Patient Assistance Program (PAP) and Ozempic Savings Card (eligible commercially insured patients may pay as little as $25/month)

Estimated based on Q1 2026 data. Prices vary by pharmacy, region, and insurance plan. Always verify current pricing with your pharmacy or plan.

Visit Novo Nordisk’s savings program ↗ | Estimate your monthly cost →

Safety & Contraindications

Ozempic carries a Boxed Warning regarding the risk of thyroid C-cell tumors (based on animal studies). The clinical relevance in humans is unknown, but the following contraindications apply:

Personal or family history of medullary thyroid carcinoma
MEN type 2 syndrome
Hypersensitivity to semaglutide
Do not use in T1D or diabetic ketoacidosis

Pregnancy: Ozempic is not recommended during pregnancy. Discontinue at least 2 months before a planned pregnancy when possible. Discuss contraception and family planning with your prescriber.

Drug interactions: May alter absorption of oral medications due to delayed gastric emptying. Use with insulin or sulfonylureas increases hypoglycemia risk.

How Does Ozempic Compare to Other Options?

See all brand comparisons →

Frequently Asked Questions

What is Ozempic approved for?

Ozempic is FDA-approved for type 2 diabetes management and cardiovascular risk reduction in T2D patients with established CVD. It is not FDA-approved for weight loss — Wegovy (same molecule, different dose) carries that indication.

Is Ozempic the same as Wegovy?

Ozempic and Wegovy both contain semaglutide but differ in approved indication and maximum dose. Ozempic's label goes up to 2.0 mg for T2D; Wegovy reaches 2.4 mg for chronic weight management.

How much weight loss can I expect on Ozempic?

In SUSTAIN trials for T2D, patients lost approximately 5–10% body weight. The STEP-1 trial using 2.4 mg (Wegovy label) showed mean weight loss of 14.9% — the higher dose specifically studied for obesity.

How do I inject Ozempic?

Ozempic comes as a pre-filled pen injector. Inject subcutaneously (under the skin) in the abdomen, thigh, or upper arm once weekly. Rotate injection sites weekly. See the official Ozempic Instructions for Use for detailed guidance.

Is Ozempic covered by Medicare?

Ozempic is often covered by Medicare Part D for type 2 diabetes. Coverage for weight loss (off-label) is typically not reimbursed. Check your specific plan formulary.

What are the main risks of Ozempic?

Key risks include thyroid C-cell tumors (boxed warning — do not use if personal/family history of medullary thyroid carcinoma or MEN2), pancreatitis, acute kidney injury, diabetic retinopathy complications, and hypoglycemia when combined with insulin or sulfonylureas.

Can I switch from Ozempic to Wegovy?

Yes, with prescriber guidance. Both are semaglutide. If switching for weight management, your prescriber may adjust your dose and restart titration. See our semaglutide conversion guide for details.

Ozempic: Complete Guide to Semaglutide (2026)